Assessment of Actual Dose Adjustment in Patients Switching From Intravenous Immunoglobulin (IGIV) Therapy to IGSC 20%

被引：0
|
作者：
Luo, M. [1 ]
Iyer, R. [1 ]
Li-McLeod, J. [1 ]
机构：
[1] Baxter Healthcare Corp, Deerfield, IL 60015 USA
来源：
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY | 2012年 / 129卷 / 02期
关键词：
D O I：
10.1016/j.jaci.2011.12.540
中图分类号：
R392 [医学免疫学];
学科分类号：
100102 ;
摘要：
引用
收藏
页码：AB110 / AB110
页数：1
相关论文
共 50 条
  • [1] Assessing real world dose adjustment in patients switching from intravenous immunoglobulin (IGIV) therapy to subcutaneous immunoglobulin (IGSC) 20%.
    Ye, Xiaolan
    Xiong, Yan
    Li-McLeod, Josephine
    PHARMACOTHERAPY, 2014, 34 (10): : E222 - E222
  • [2] Assessing Real World Dose Adjustment in Patients Switching from Intravenous Immunoglobulin (IGIV) Therapy to Subcutaneous Immunoglobulin (IGSC) 20%
    Luo, Michelle
    Iyer, Ravi
    Xiong, Yan
    Li-McLeod, Josephine
    JOURNAL OF CLINICAL IMMUNOLOGY, 2012, 32 (02) : 392 - 392
  • [3] EVIDENCE OF ACTUAL DOSE ADJUSTMENT IN PATIENTS SWITCHING FROM INTRAVENOUS IMMUNOGLOBULIN (IGIV) THERAPY TO IGSC 20%: A STUDY OF THREE US SPECIALTY PHARMACY DATABASES
    Luo, M.
    Iyer, R.
    Xiong, Y.
    Li-McLeod, J.
    JOURNAL OF CLINICAL IMMUNOLOGY, 2012, 32 : 164 - 165
  • [4] Switching From Intravenous Immunoglobulin (IGIV) Therapy to IGSC 20%: Estimated Impact on Dosing Requirements and Cost of Therapy
    Iyer, R.
    Luo, M.
    Li-McLeod, J.
    JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 2012, 129 (02) : AB109 - AB109
  • [5] Estimated Impact on Drug Utilization and Costs Associated with Switching from Intravenous Immunoglobulin (IGIV) Therapy to Subcutaneous Immunoglobulin (IGSC) 20% Therapy
    Luo, Michelle
    Iyer, Ravi
    Li-McLeod, Josephine
    JOURNAL OF CLINICAL IMMUNOLOGY, 2012, 32 (02) : 399 - 399
  • [6] Evaluating Dose Ratio of Subcutaneous to Intravenous Immunoglobulin Therapy Among Patients With Primary Immunodeficiency Disease Switching to 20% Subcutaneous Immunoglobulin Therapy
    Krishnarajah, Girishanthy
    Lehmann, Jee-Yeon K.
    Ellman, Brian
    Bhak, Rachel H.
    DerSarkissian, Maral
    Leader, Deane, Jr.
    Bullinger, Ann L.
    Duh, Mei Sheng
    AMERICAN JOURNAL OF MANAGED CARE, 2016, 22 (15): : S475 - S481
  • [7] Efficacy and Safety of IgPro20, a 20% Immunoglobulin for Subcutaneous Administration, in Patients with Primary Immunodeficiency Switching from Intravenous Replacement Therapy
    Jolles, Stephen
    Cristea, Victor
    Wahn, Volker
    Debre, Marianne
    Longhurst, Hilary
    Zenker, Othmar
    Peter, Hans-Hartmut
    Borte, Michael
    CLINICAL IMMUNOLOGY, 2010, 135 : S86 - S87
  • [8] HIGH-DOSE INTRAVENOUS IMMUNOGLOBULIN THERAPY IN PATIENTS WITH IMMUNE THROMBOCYTOPENIC PURPURA
    CARROLL, RR
    NOYES, WD
    KITCHENS, CS
    JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1983, 249 (13): : 1748 - 1750
  • [9] Safety of Intravenous Immunoglobulin (IGIV) Therapy in Patients with Probable Alzheimer's Disease (AD): a Randomized, Placebo-Controlled Clinical Study
    Gelmont, David
    Thomas, Ronald G.
    Dyck-Jones, Jacqueline A.
    Fritsch, Sandor
    Aisen, Paul
    Relkin, Norman
    JOURNAL OF CLINICAL IMMUNOLOGY, 2015, 35 : S53 - S54
  • [10] Shift from intravenous or 16% subcutaneous replacement therapy to 20% subcutaneous immunoglobulin in patients with primary antibody deficiencies
    Canessa, Clementina
    Iacopelli, Jessica
    Pecoraro, Antonio
    Spadaro, Giuseppe
    Matucci, Andrea
    Milito, Cinzia
    Vultaggio, Alessandra
    Agostini, Carlo
    Cinetto, Francesco
    Danieli, Maria Giovanna
    Gambini, Simona
    Marasco, Carolina
    Trizzino, Antonino
    Vacca, Angelo
    De Mattia, Domenico
    Martire, Baldassarre
    Plebani, Alessandro
    Di Gioacchino, Mario
    Gatta, Alessia
    Finocchi, Andrea
    Licciardi, Francesco
    Martino, Silvana
    De Carli, Marco
    Moschese, Viviana
    Azzari, Chiara
    INTERNATIONAL JOURNAL OF IMMUNOPATHOLOGY AND PHARMACOLOGY, 2017, 30 (01) : 73 - 82
12345